Muna Therapeutics Partners with GSK to Develop Novel Treatments for Alzheimer’s Disease
Shots:
- Muna & GSK have partnered to identify drug targets for Alzheimer's disease using Muna's MiND-MAP platform, which uses spatial transcriptomics on brain samples
- The alliance will utilize Muna’s knowledge of mapping the brain’s response to pathological protein aggregates and its all-in-human platform to uncover cellular mechanisms, gene networks & molecular interactions behind the brain, validating drug targets with humanized models and patient-derived insights
- Muna will enhance its MiND-MAP dataset and lead target discovery plus receive ~$35.44M (€33.5M) upfront, up to $147.9M (€140M) per target in milestones & net-sales-based tiered royalties, while GSK handles drug development, manufacturing & commercialization
Ref: Muna Therapeutics | Image: Muna Therapeutics
Related News:- GSK’s Menveo Secures the EC’s Approval to Prevent Invasive Meningococcal Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
